Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having substantially de-risked the technology, Renephra is raising £1.2million to design the TFR device, and to obtain the required regulatory approvals in Europe.
Deepbridge Capital | April 2016
Renephra has received investment from DeepBridge Capital.
SBRI Healthcare | March 2016
Renephra has been awarded £100k SBRI Healthcare development contract for Urgent and Emergency Care Services.
“This work was commissioned and funded by the SBRI Healthcare programme. SBRI Healthcare is an NHS England initiative, championed by the Academic Health Science Networks (AHSNs). The views expressed in the publication are those of the author(s) and not necessarily those of the SBRI Healthcare programme or its stakeholders.”
MedTech Strategist | June 2015
Start-Ups to Watch: “Renephra. Home-Based Fluid Removal for Fluid Overload and Chronic Edema.” by Mary Stuart.
© 2017 Renephra Ltd. All rights reserved.